ArticleCurrent medicinal chemistry2026
Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCircadian rhythm genes (CRGs) play a significant role in the pathogenesis of various cancers, yet their impact on bladder cancer (BC) remains to be fully elucidated. EZH2, as a potential oncological biomarker, lacks clear delineation regarding its prognostic significance in BC. Furthermore, the effect of anesthesia on circulating tumor cells (CTCs) in cancer patients is scarcely studied.
methodIn this study, we developed a bioinformatics signature based on CRGs to assess the prognosis of BC patients and investigated the expression of EZH2 in BC and its correlation with patient outcomes through clinical sample analysis. Furthermore, we collected blood samples from BC patients before anesthesia and two hours post-anesthesia, enriched for CTCs, and analyzed the expression of EZH2 to evaluate the impact of anesthesia on the quantity of CTCs and their EZH2 expression status.
resultsOur prognostic model identified EZH2 as a key determinant of BC prognosis, with the high expression of EZH2 significantly associated with poor patient outcomes. Experimental validation revealed a significant increase in the number of EZH2+ CTCs after anesthesia in BC patients. These findings suggest that anesthesia may facilitate BC metastasis by increasing the number of EZH2+ CTCs. DISCUSSION: The findings highlight the prognostic value of CRGs and EZH2 in BC, providing new insights into tumor biology and metastasis. Furthermore, this study suggests anesthesia may influence tumor progression by modulating EZH2 expression in CTCs, underscoring the need for careful anesthetic selection in BC patients.
conclusionThis study unveils the potential value of CRGs and EZH2 in the prognostic assessment of BC and reports for the first time that anesthesia may influence tumor metastasis by modulating the expression of EZH2 in CTCs. These results offer new biomarkers for the prognosis and treatment of BC and provide novel insights into the role of anesthesia in cancer metastasis.
Indexed as
Identifiers
40735993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.